Genvor enters $800K convertible note deal with warrants and advisory pact

On April 16, 2026, the Company also entered into an Advisory Agreement (the “ Advisory Agreement ”) with Brio Advisory Group (the “ Consultant ”), pursuant to which the Consultant will provide the Company advisory services in connection with strategic initiatives, capitalization, financial and other planning, due diligence, financing efforts, and an Exchange Listing, and the Company will issue to the Consultant shares of preferred stock which will be valued as follows: (i) $300,000 per Tranche ($1,200,000 in the aggregate if all four Tranches of funding under the Note are funded to the Company) at the time of the Exchange Listing, or (ii) if there is no Exchange Listing within one year of the date of the Advisory Agreement, that will convert into $300,000 of Company common stock per Tranche based on the 5-day average closing price at such time, but in no event at less than $1.00 per share.

Effective April 16, 2026, Genvor Incorporated (the “ Company ”) entered into a securities purchase agreement (the “ SPA ”) with Evergreen Capital Management LLC (“ Evergreen ”), pursuant to which the Company sold, and Evergreen purchased, (i) a convertible promissory note in the aggregate principal amount of up to $800,000 (the “ Note ”), and (ii) warrants to purchase up to 600,000 shares of Company common stock (the “ Warrants ”), for an aggregate purchase price of up to $666,668 (the “ Purchase Price ”).